{"id":"tp05","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TP05 inhibits phosphodiesterase 4 enzyme activity in immune and inflammatory cells, leading to decreased production of pro-inflammatory mediators such as TNF-α and IL-23. This mechanism reduces skin inflammation and is intended for treatment of inflammatory skin conditions.","oneSentence":"TP05 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:33.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT05387083","phase":"PHASE2","title":"A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2022-12-12","conditions":"Healthy Volunteer","enrollment":30},{"nctId":"NCT05720364","phase":"PHASE1","title":"Study to Evaluate the Food Effect of TP-05 in Healthy Participants","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2023-01-19","conditions":"Healthy","enrollment":42},{"nctId":"NCT05138796","phase":"PHASE1","title":"A Pharmacokinetic Study of TP-05 in Healthy Subjects","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2021-05-06","conditions":"Healthy","enrollment":67},{"nctId":"NCT01903252","phase":"PHASE3","title":"TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2013-07","conditions":"Acute Ulcerative Colitis","enrollment":817},{"nctId":"NCT02306798","phase":"PHASE1","title":"TP0502-B-Pharmaco-Scintigraphic-Study","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2013-09","conditions":"Ulcerative Colitis","enrollment":9},{"nctId":"NCT02306785","phase":"PHASE1","title":"TP0502-Pharmaco-Scintigraphic-Study and Amendment","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2012-10","conditions":"Ulcerative Colitis","enrollment":26},{"nctId":"NCT02306772","phase":"PHASE1","title":"TP0501 - Pharmaco-Scintigraphic-Study","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2011-12","conditions":"Ulcerative Colitis","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mesalazine","Mesalazine 1600 mg"],"phase":"phase_3","status":"active","brandName":"TP05","genericName":"TP05","companyName":"Tillotts Pharma AG","companyId":"tillotts-pharma-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TP05 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}